GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Total Receivables

Apures Co (XKRX:149300) Total Receivables : ₩259.0 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co Total Receivables?

Apures Co's Total Receivables for the quarter that ended in Dec. 2023 was ₩259.0 Mil.


Apures Co Total Receivables Historical Data

The historical data trend for Apures Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Total Receivables Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.68 42.03 93.73 61.10 259.04

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.68 42.03 93.73 61.10 259.04

Apures Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Apures Co Total Receivables Related Terms

Thank you for viewing the detailed overview of Apures Co's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Apures Co (XKRX:149300) Business Description

Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines